Shares of Biodexa Pharmaceuticals Plc (NASDAQ:BDRX – Get Free Report) traded up 6.9% during trading on Thursday . The stock traded as high as $1.93 and last traded at $1.39. 62,690,079 shares traded hands during trading, an increase of 7,495% from the average session volume of 825,372 shares. The stock had previously closed at $1.30.
Biodexa Pharmaceuticals Stock Performance
The firm’s 50 day moving average price is $1.48 and its two-hundred day moving average price is $3.28.
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Read More
- Five stocks we like better than Biodexa Pharmaceuticals
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Turbulence for Joby Shares: What’s Behind the Recent Dip?
- Investing in Travel Stocks Benefits
- Why Carnival Could Be the Ultimate Non-Tech Growth Stock
- What is the FTSE 100 index?
- Super Micro Computer Stock Clears New Path Higher on Saudi Orders
Receive News & Ratings for Biodexa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodexa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
